12:00 AM
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TriAb: Phase II

Preliminary data from an ongoing Phase II study showed that TriAb elicited an immune response in 20 of 21 patients. There...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >